BrightGene Bio-Medical Technology Co., Ltd. Reports Positive Phase 1 Results for Oral GLP-1/GIP Drug

BrightGene Bio-Medical Technology Co., Ltd. Reports Positive Phase 1 Results for Oral GLP-1/GIP Drug

By, Admin 26 March 2026

The obesity drug race just got more crowded—and more competitive. BrightGene has announced positive topline Phase 1 results for BGM0504, an investigational oral GLP-1/GIP dual receptor agonist, tested across studies in both China and the United States.

Why This Matters?

The GLP-1 space is already dominated by injectable blockbusters.

An effective oral alternative could be a major disruption.

  • Easier administration
  • Better patient compliance
  • Broader adoption

What Is BGM0504?

BGM0504 is a next-generation metabolic therapy targeting:

  • GLP-1 receptor (controls appetite and glucose)
  • GIP receptor (enhances metabolic effects)

This dual-action approach is designed to:

  • Improve weight loss outcomes
  • Enhance metabolic control

And importantly—it's being developed as:

  • Oral formulation (current focus)
  • Subcutaneous version (more advanced stage)

Phase 1 Results: Key Takeaways

1. Strong Safety Profile

Across both trials:

  • No serious adverse events reported
  • Side effects were mostly:
    • Gastrointestinal
    • Mild to moderate
    • Temporary

This aligns with the known profile of GLP-1–based therapies.

2. Early Signs of Weight Loss

Even in early-stage trials, results look promising.

China Study (4 weeks)

  • Mean weight reduction: 1.0% to 5.6%

U.S. Study (5–8 weeks)

  • Mean weight reduction: 2.7% to 8.2%

Clear dose-response relationship observed.

Study Design Breakdown

China Phase 1 Study

  • Participants: 75
  • Design: Randomized, double-blind, placebo-controlled
  • Dosing: 10 mg to 80 mg (once daily)
  • Duration: 4 weeks

Additional insights:

  • Steady-state drug levels reached in 2–3 weeks
  • Exposure increased proportionally with dose

U.S. Phase 1 Study

  • Participants: 80
  • Design: Randomized, placebo-controlled, multiple ascending dose
  • Dosing: 20 mg to 80 mg
  • Duration: 5–8 weeks

Results reinforced:

  • Safety consistency
  • Dose-dependent weight loss

Pipeline Positioning

BGM0504 is not just an early-stage asset.

Development Status

  • Oral version: Phase 1 (current results)
  • Subcutaneous version:
    • Phase 2 completed (China)
    • Bridging study completed (U.S.)
    • Phase 3 trials ongoing

This dual-formulation strategy gives BrightGene flexibility across markets.

What Comes Next?

  • Full data presentation expected at a scientific conference later this year
  • Continued clinical development to validate:
    • Long-term safety
    • Sustained efficacy

The Bigger Picture

The obesity therapeutics market is evolving fast. Key trends:

  • Shift toward dual-agonist mechanisms
  • Push for oral alternatives
  • Demand for better tolerability + convenience

BGM0504 sits right at the intersection of all three.

Final Takeaway

Early—but meaningful. BGM0504 shows:

  • Encouraging safety profile
  • Clear early efficacy signals
  • Strong positioning in a competitive class

But here’s the reality: Phase 1 success doesn’t guarantee Phase 3 outcomes. The real test lies ahead. If BrightGene can replicate these results at scale, this could become a serious contender in the global obesity drug market.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!